Meeting
2013 ASCO Annual Meeting
Impact of cetuximab on chemoradiation use in older patients with locally advanced head and neck cancer.
Authors
Shrujal S. Baxi
Memorial Sloan-Kettering Cancer Center, New York, NY
Shrujal S. Baxi , Eric Jeffrey Sherman , Coral L Atoria , Nancy Y. Lee , David G. Pfister , Elena B. Elkin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Outcomes and Quality of Care
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6594)
DOI
10.1200/jco.2013.31.15_suppl.6594
Abstract #
6594
Poster Bd #
18B
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
NANORAY-312: A phase III pivotal study of NBTXR3 activated by investigator’s choice of radiotherapy alone or radiotherapy in combination with cetuximab for platinum-based chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma.
First Author: Christophe Le Tourneau
Poster
2014 ASCO Annual Meeting
Cisplatin versus cetuximab plus concomitant radiotherapy in locally advanced head and neck cancer: A meta-analysis of published trials.
First Author: Sandro Barni
Poster
2023 ASCO Annual Meeting
Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
First Author: Peter John Oppelt
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Toxicities and outcomes of neoadjuvant treatment in elderly patients with locally advanced rectal cancer: A scoping review.
First Author: Ruba Ahmed Mohammed Hamed